NATALIA LAPTEVA to Female
This is a "connection" page, showing publications NATALIA LAPTEVA has written about Female.
Connection Strength
0.087
-
Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. J Immunother. 2015 Jan; 38(1):24-36.
Score: 0.017
-
Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity. J Immunother. 2009 Feb-Mar; 32(2):145-56.
Score: 0.011
-
Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial. Nat Med. 2026 Jan; 32(1):258-269.
Score: 0.009
-
CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther. 2005 Jan; 12(1):84-9.
Score: 0.008
-
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature. 2025 01; 637(8047):940-946.
Score: 0.008
-
Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors. J Clin Oncol. 2024 08 10; 42(23):2769-2779.
Score: 0.008
-
Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial. Nat Cancer. 2024 06; 5(6):880-894.
Score: 0.008
-
NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors. Cancer Immunol Res. 2019 03; 7(3):363-375.
Score: 0.006
-
Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia. Cytotherapy. 2017 10; 19(10):1225-1232.
Score: 0.005
-
The E3 ligase c-Cbl regulates dendritic cell activation. EMBO Rep. 2011 Sep 01; 12(9):971-9.
Score: 0.003
-
A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy. J Clin Invest. 2011 Apr; 121(4):1524-34.
Score: 0.003